Efficacy of oral L-ornithine-L-aspartate in cirrhotic patients with hyperammonemic hepatic encephalopathy. Results of a randomized, lactulose-controlled study.

[1]  A. Mas.  Hepatic Encephalopathy: From Pathophysiology to Treatment , 2006, Digestion.

[2]  J. Talwalkar,et al.  Influence of recent advances in medical management on clinical outcomes of cirrhosis. , 2005, Mayo Clinic proceedings.

[3]  Dong Ki Lee,et al.  Comparison of Rifaximin and Lactulose for the Treatment of Hepatic Encephalopathy: A Prospective Randomized Study , 2005, Yonsei medical journal.

[4]  Ming Chen,et al.  [Therapeutic effect of L-ornithine-L-aspartate on liver cirrhosis complicated by hepatic encephalopathy]. , 2005, Di 1 jun yi da xue xue bao = Academic journal of the first medical college of PLA.

[5]  R. Jalan,et al.  Dispelling myths in the treatment of hepatic encephalopathy , 2005, The Lancet.

[6]  M. Uribe,et al.  Treatment of chronic portal—Systemic encephalopathy with vegetable and animal protein diets , 1982, Digestive Diseases and Sciences.

[7]  H. Conn.  Trailmaking and number-connection tests in the assessment of mental state in portal systemic encephalopathy , 1977, The American Journal of Digestive Diseases.

[8]  H. Timmerman,et al.  Effect of antibiotics, prebiotics and probiotics in treatment for hepatic encephalopathy. , 2005, Medical hypotheses.

[9]  D. Hãussinger,et al.  Nitrogen metabolism in liver : structural and functional organization and physiological relevance , 2005 .

[10]  A. Whittemore,et al.  Role of ethnicity in risk for hepatocellular carcinoma in patients with chronic hepatitis C and cirrhosis. , 2004, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[11]  R. Esteban,et al.  Normal protein diet for episodic hepatic encephalopathy: results of a randomized study. , 2004, Journal of hepatology.

[12]  L. Gluud,et al.  Non-absorbable disaccharides for hepatic encephalopathy: systematic review of randomised trials , 2004, BMJ : British Medical Journal.

[13]  D. Häussinger,et al.  Clinical Efficacy of L-Ornithine–L-Aspartate in the Management of Hepatic Encephalopathy , 2002, Metabolic Brain Disease.

[14]  R. Butterworth.  Pathophysiology of Hepatic Encephalopathy: A New Look at Ammonia , 2002, Metabolic Brain Disease.

[15]  R. Butterworth,et al.  L-Ornithine-L-Aspartate in Experimental Portal-Systemic Encephalopathy: Therapeutic Efficacy and Mechanism of Action , 1998, Metabolic Brain Disease.

[16]  M. Uribe,et al.  Hepatic encephalopathy: a review. , 2003, Annals of hepatology.

[17]  J. Rodés,et al.  Comparison of rifaximin and lactitol in the treatment of acute hepatic encephalopathy: results of a randomized, double-blind, double-dummy, controlled clinical trial. , 2003, Journal of hepatology.

[18]  D. Häussinger,et al.  Management of hepatic encephalopathy , 2002, Journal of gastroenterology and hepatology.

[19]  A. Burroughs,et al.  Assessing health‐related quality of life pre– and post–liver transplantation: A prospective multicenter study , 2002, Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society.

[20]  P. Thuluvath,et al.  Effect of race on outcome of orthotopic liver transplantation: a cohort study , 2002, The Lancet.

[21]  S. Brusilow.  Hyperammonemic encephalopathy. , 2002, Medicine.

[22]  A. Blei,et al.  Hepatic Encephalopathy. , 2001, The American journal of gastroenterology.

[23]  M. Hudson,et al.  Effect of l-ornithine-l-aspartate on patients with and without TIPS undergoing glutamine challenge: a double blind, placebo controlled trial , 2000, Gut.

[24]  William M. Lee,et al.  Racial differences in responses to therapy with interferon in chronic hepatitis C , 1999, Hepatology.

[25]  R. Butterworth,et al.  L‐Ornithine‐L‐aspartate lowers plasma and cerebrospinal fluid ammonia and prevents brain edema in rats with acute liver failure , 1999, Hepatology.

[26]  P. Malfertheiner,et al.  Oral L-ornithine-L-aspartate therapy of chronic hepatic encephalopathy: results of a placebo-controlled double-blind study. , 1998, Journal of hepatology.

[27]  M. Uribe,et al.  Beneficial effect of carbohydrate maldigestion induced by a disaccharidase inhibitor (AO-128) in the treatment of chronic portal-systemic encephalopathy. A double-blind, randomized, controlled trial. , 1998, Scandinavian journal of gastroenterology.

[28]  F. Gaunitz,et al.  Treatment of cirrhotic rats with L-ornithine-L-aspartate enhances urea synthesis and lowers serum ammonia levels. , 1997, The Journal of pharmacology and experimental therapeutics.

[29]  R Williams,et al.  Treatment of hepatic encephalopathy. , 1997, The New England journal of medicine.

[30]  G. Kircheis,et al.  Therapeutic efficacy of L‐ornithine‐L‐aspartate infusions in patients with cirrhosis and hepatic encephalopathy: Results of a placebo‐controlled, double‐blind study , 1997, Hepatology.

[31]  A. Herneth,et al.  Newer Approaches to Therapy of Hepatic Encephalopathy , 1996, Seminars in liver disease.

[32]  R. Hawkins,et al.  Metabolic Abnormalities and Grade of Encephalopathy in Acute Hepatic Failure , 1994, Journal of neurochemistry.

[33]  Beth Dawson,et al.  Basic & Clinical Biostatistics , 1990 .

[34]  F. Henry,et al.  Cost effectiveness. , 1980, The Ohio State medical journal.